Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loxenatide for diabetic cerebral small vessel disease
ChiCTR2200055231Phase 3Recruiting
- Sponsor
- The Seventh Affiliated Hospital, Sun Yat-Sen University
- Start
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of loxenatide in Cerebral Small Vessel Disease (CSVD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Seventh Affiliated Hospital, Sun Yat-Sen University. Primary endpoints: MRI changes of cerebral small vessel lesions and Cognitive function score. Started Jun 2022; status: recruiting.
02
Drugs
loxenatide
03
Conditions
Cerebral Small Vessel Disease (CSVD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200055231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055231.